NRXP (NRX Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals 5-Year Dividend Growth Rate?

NRX Pharmaceuticals's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

NRX Pharmaceuticals's Dividend Payout Ratio for the three months ended in Dec. 2024 was 0.00. As of today, NRX Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of NRX Pharmaceuticals's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, NRX Pharmaceuticals's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's 5-Year Dividend Growth Rate falls into.

Save Embed

;

Save Embed

;

NRX Pharmaceuticals 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

NRX Pharmaceuticals (NAS:NRXP) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NRX Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.631
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NRX Pharmaceuticals 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » 5-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

B1Q:Germany

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Executives

Jonathan C Javitt	director, 10 percent owner, officer: Chief Scientist	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz	director	C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard	director, officer: Chief Executive Officer	1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt	10 percent owner	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn	director	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg	officer: Chief Financial Officer	C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof	officer: Chief Comm. & Patient Officer	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault	officer: General Counsel & Secretary	1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster	director	C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
William Fricker	officer: CFO & Treasurer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Big Rock Partners Sponsor, Llc	10 percent owner	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Richard Ackerman	director, 10 percent owner, officer: President & CEO	2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483